Article Text

PDF

Basic fibroblast growth factor treatment for non-steroidal anti-inflammatory drug associated gastric ulceration.
  1. M A Hull,
  2. D J Cullen,
  3. N Hudson,
  4. C J Hawkey
  1. Division of Gastroenterology, University Hospital, Queen's Medical Centre, Nottingham.

    Abstract

    An open, pilot study tested the safety and efficacy of an acid stable form of the angiogenic protein basic fibroblast growth factor (bFGF) for healing of non-steroidal anti-inflammatory drug (NSAID) associated gastric ulcers in five patients with nine gastric ulcers that were resistant to conventional treatment (4) or had relapsed (5). Oral bFGF treatment for four weeks was safe and well tolerated. There was no evidence of systemic absorption. After four weeks, four ulcers had healed and there was a 89 (3)% mean (SEM) reduction in the area of the others. A controlled, comparative trial of this novel growth factor treatment is warranted.

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.